መነሻ › ክሮኒክ ሊምፎሳይቲክ ሉኬሚያ › Texas

በTexas ለክሮኒክ ሊምፎሳይቲክ ሉኬሚያ የሚደረጉ ክሊኒካዊ ጥናቶች

ለክሮኒክ ሊምፎሳይቲክ ሉኬሚያ የሚደረጉ 38 ጥናቶች በTexas ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።

በTexas ውስጥ ያሉ ከተሞች

Official study text (English)

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

Houston Methodist Hospital, Houston
Texas Children's Hospital, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 1

እስከ እድሜ 75 · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT01853631

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Hendrick Medical Center, Abilene

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 65 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT07321652

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

The Don and Sybil Harrington Cancer Center, Amarillo
UT MD Anderson Cancer Center, Houston
Audie L Murphy VA Hospital, San Antonio

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናትጤናማ ተሳታዮች ይቀበላሉ

እድሜ ከ40 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT05334069

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Research Site, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ሴፕቴ 2026 · NCT06542250

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Texas Oncology Baylorcharles A Sammons Cancer Center, Dallas
Texas Oncology San Antonio Medical Center Usor, San Antonio
Texas Oncology Tyler, Tyler

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT06943872

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Md Anderson Cancer Center, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT05006716

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Texas Oncology Tyler, Tyler

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT07277231

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Baylor Scott and White Health, Temple
Texas Oncology Tyler, Tyler

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT06846671

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Md Anderson Cancer Center, Houston
Texas Oncology Palestine Cancer Center, Palestine

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT06973187

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

PatientCare Clinical Research LLC ( Site 5435), Sugar Land

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ24 ሴፕቴ 2026 · NCT05947851

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Texas Oncology - Central/South Texas ( Site 8008), Austin
The Center for Cancer and Blood Disorders ( Site 0032), Fort Worth
Texas Oncology - San Antonio ( Site 8006), San Antonio
እና 1 ተጨማሪ

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ24 ሴፕቴ 2026 · NCT06136559

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Texas Oncology - Paris, Fort Worth
US Oncology - Texas Oncology, Kyle

ተሳታዮችን በመፈለግ ላይደረጃ 4

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT07218341

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

The University of Texas MD Anderson Cancer Center, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ21 ሴፕቴ 2026 · NCT07648264

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Texas Oncology - Center South, Austin

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT07221500

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

M D Anderson Cancer Center, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ10 ሴፕቴ 2026 · NCT04169737

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

Research Site, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ8 ሴፕቴ 2026 · NCT06564038

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Baylor University Medical Center, Dallas

ተሳታዮችን በመፈለግ ላይደረጃ 1

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ8 ሴፕቴ 2026 · NCT03666000

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Baylor Scott & White Health, Dallas
MD Anderson, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ3 ሴፕቴ 2026 · NCT04588922

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

Texas Oncology - West Texas, Midland

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ31 ኦገስ 2026 · NCT07516093

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

Texas Oncology - Northeast, Tyler

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ኦገስ 2026 · NCT07520006

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Lumi Research, Kingwood

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ኦገስ 2026 · NCT05254743

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

University of Texas MD Anderson Cancer Center, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ ከ13 እስከ 90 · ሁሉም ጾታዎች · የተሻሻለው በ6 ኦገስ 2026 · NCT06533579

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

UT Southwestern Medical Center, Dallas

ተሳታዮችን በመፈለግ ላይደረጃ 1

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ31 ጁላይ 2026 · NCT06708897

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

MD Anderson Cancer Center, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ጁላይ 2026 · NCT06967610

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

MD Anderson Cancer Center, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 1

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ጁላይ 2026 · NCT05131022

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

Texas Oncology - Sammons Cancer Center, Dallas

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ12 ጁን 2026 · NCT07271667

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

USO-Texas Oncology-Central/South Texas, Austin
Sarah Cannon Research Institute/SCRI, The Woodlands

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ19 ሜይ 2026 · NCT06588478

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

MD Anderson Cancer Center, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 1

እድሜ 13 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ5 ሜይ 2026 · NCT04771572

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

University of Texas(UT) Southwestern-Children's Medical Center, Dallas

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ ከ12 እስከ 95 · ሁሉም ጾታዎች · የተሻሻለው በ15 ኤፕሪ 2026 · NCT04329728

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Texas Oncology - Austin Midtown /ID# 268152, Austin
University of Texas - Southwestern Medical Center /ID# 266528, Dallas

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ9 ኤፕሪ 2026 · NCT06428019

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

MD Anderson Cancer Center, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 1

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ማርች 2026 · NCT04830137

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

University of Texas MD Anderson Cancer Center, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 4

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ማርች 2026 · NCT06876662

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

University of Texas MD Anderson Cancer Center, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 4

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ማርች 2026 · NCT06876649

Study of SGR-1505 in Mature B-Cell Neoplasms

University of Texas Southwestern, Dallas

ተሳታዮችን በመፈለግ ላይደረጃ 1

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ፌብሩ 2026 · NCT05544019

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Oncology Consultants, Houston
University of Texas MD Anderson Cancer Center, Houston

ተሳታዮችን በመፈለግ ላይደረጃ 1

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ10 ዲሴም 2025 · NCT05602363

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

SCRI, San Antonio

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ኖቬም 2025 · NCT05643742

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

University of Texas Southwestern Medical Center, Dallas

ተሳታዮችን በመፈለግ ላይደረጃ 1

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2025 · NCT05780034

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

UT Southwestern Medical Center, Dallas

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ4 ኦገስ 2022 · NCT04502394

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።